Orthocell Says March Quarter Revenue in Line With Prior Quarter; Shares Down 5%
MT Newswires Live
Apr 20
Orthocell (ASX:OCC) said it achieved a revenue of AU$3.2 million in the March quarter, in line with the prior quarter and primarily driven by sales of its nerve repair product, Remplir, according to a Monday Australian bourse filing.
The company expects a material uplift in US revenue in the upcoming quarters after the establishment of a commercial distribution platform in the country, with its network expanded to cover over 16 states and around 40% of the population.
Regulatory approval for the commercial distribution of Remplir in the US and UK is anticipated in the second half of 2026.
Orthocell's shares fell past 5% in recent trading on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.